Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
EBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares OutstandingShares Outstanding
Ratios

Acro Biomedical (ACBM) Shares Outstanding (2016 - 2025)

Acro Biomedical has reported Shares Outstanding over the past 10 years, most recently at $60.0 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $60.0 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $60.0 million (changed 0.0% YoY), and the annual figure for FY2025 was $60.0 million, changed 0.0%.
  • Shares Outstanding for Q4 2025 was $60.0 million at Acro Biomedical, roughly flat from $60.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding for ACBM hit a ceiling of $60.0 million in Q4 2021 and a floor of $47.8 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $60.0 million (2021), compared with a mean of $59.3 million.
  • Peak annual rise in Shares Outstanding hit 25.72% in 2021, while the deepest fall reached 0.0% in 2021.
  • Acro Biomedical's Shares Outstanding stood at $60.0 million in 2021, then changed by 0.0% to $60.0 million in 2022, then changed by 0.0% to $60.0 million in 2023, then changed by 0.0% to $60.0 million in 2024, then changed by 0.0% to $60.0 million in 2025.
  • The last three reported values for Shares Outstanding were $60.0 million (Q4 2025), $60.0 million (Q3 2025), and $60.0 million (Q2 2025) per Business Quant data.